• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks
    life science investing

    Medication Errors Affect 1.2 Million US Hospitalizations a Year, Study Shows

    Charlotte McLeod
    Dec. 10, 2012 12:28PM PST
    Life Science Investing

    Peer-reviewed journal American Health & Drug Benefits reported that its new study indicates that medication errors, specifically those related to injectable medications, affect 1.2 million US-based hospitalizations a year. These errors, also known as preventable adverse drug events, result in an average of $600,000 per year in extra costs per hospital.

    Peer-reviewed journal American Health & Drug Benefits reported that its new study indicates that medication errors, specifically those related to injectable medications, affect 1.2 million US-based hospitalizations a year. These errors, also known as preventable adverse drug events, result in an average of $600,000 per year in extra costs per hospital.

    As quoted in the market news:

    Based on this medication-level analysis of reported harmful errors and the frequency of inpatient administrations with actuarial projections, we estimate that preventable ADEs associated with injectable medications impact 1.2 million hospitalizations annually. Using a matched cohort analysis of healthcare claims as a basis for evaluating incremental costs, we estimate that inpatient preventable ADEs associated with injectable medications increase the annual US payer costs by $2.7 billion to $5.1 billion, averaging $600,000 in extra costs per hospital.

    Click here to read the full American Health & Drug Benefits report.

    life science investing
    The Conversation (0)

    Go Deeper

    AI Powered
    Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

    Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

    Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

    Latest News

    InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

    Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

    Nextech3D.ai: Disrupting the Global Events Management Industry with AI and Blockchain

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
      • Electric Vehicles
    • Agriculture
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Energy
      • Uranium
      • Oil and Gas
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Robotics
      • Crypto
      • Cleantech
    Life Science
      • Biotech
      • Cannabis
      • Pharmaceuticals

    Featured Life Science Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES